Current Status of Nuclear Medicine Practice in the Middle East

Abstract

The practice of nuclear medicine (NM) in the Middle East region has experienced an important growth in the last 2 decades and has become crucial in providing healthcare to the region's population of about 395 million people. Even though there are some countries in which the services provided are limited to basic coverage of studies with (99m)Tc and (131)I, most have well-established practices covering most of the available studies in this medical specialty; this is the case in for example, Iran, Israel, Kuwait, Saudi Arabia, and Turkey. According to data provided by the NM professionals in the 17 countries included in the present publication, which was collected by the International Atomic Energy Agency in 2015, the total number of gamma cameras in the region is 910 with an average of 2.3 gamma cameras per million inhabitants. Out of these, 107 cameras, or 12%, are SPECT/CT cameras. There are 194 operating PET/CT scanners, translating to one PET/CT scanner for 2.04 million people on average. The availability of PET/CT scanners in relation to population is the highest in Lebanon and Kuwait, with 2.2 and 1.7 scanners per million people, respectively. There is a total of 628 NM centers in the 17 countries, whereas most NM centers belong to the public healthcare system and in most of the countries are widely spread and not confined exclusively to capital cities. As for the radionuclide therapies, (131)I is used regularly in diagnostic workup as well as in therapeutic applications in all the countries included in this analysis. Only five countries have the capability of assembling (99)Mo-(99m)Tc generators (Egypt, Iran, Saudi Arabia, Israel, and Turkey), and cold kits are produced in several countries. Although there are no capabilities in the region to produce (99)Mo from nuclear reactors, a total of 46 cyclotrons are operated for production of PET radionuclides. The most widely used PET tracer in the region is (18)F-FDG followed by (18)F-NaF; concomitantly, the availability of (68)Ge-(68)Ga generators is increasing and studies involving prostate-specific membrane antigen or DOTA-chelated peptides or both are performed in at least seven countries. Although therapeutic radionuclide agents are mostly imported from outside the region, this does not limit the availability of therapies with (90)Y, (153)Sm, (177)Lu, (131)I, (188)Re, and (89)Sr. Nevertheless, therapies based on alpha particle emitters are still largely not available in the region and are currently only available in Israel and Turkey. Regarding human resources, according to the data provided there are 1157 NM physicians, 1953 technologists, 586 medical physicists, and 173 radiopharmacists or radiochemists in the region. Approximately half of all available human resources are accounted for by Turkey. The region has great potential for expanding the applications of NM; this becomes especially important in view of the high prevalence of non-communicable diseases. Further increasing awareness of the clinical applications of NM in healthcare and strengthening tec...

Variations in the practice of molecular radiotherapy and implementation of dosimetry: results from a European survey

“…The number of centers administering MRT in different countries was reported, identifying a total of 630 centers. In addition to that survey [ 3 ], a few national surveys have been identified [ 4 , 5 ], as well as one reviewing nuclear medicine in the Middle East [ 6 ].…”

Rhenium-188 Radiochemistry: Challenges and Prospects

“…Re-DMSA complex, with potential application in radionuclide therapy of medullary thyroid carcinoma and bone metastases in prostate cancer, which also emerged in the 1990s, [4][5][6][7] Tc, most of these agents and methods were established in the 1990s and although clinical applications have begun to take hold (all of which are based on "phase 1" and "phase 2" chemistry described above, as illustrated in other contributions to this issue), little new 188 Re chemistry development has occurred since that time. This unfortunate trend is reflected in the chart shown in Figure 1, Re radionuclide therapies in some countries, [9,10] 188 Re generator availability is improving again and the scene is set for a resurgence of development of both 99m Tc and 188 Re chemistry development, reversing the recent trend (see Figure 1) that has seen the collapse of basic research on the chemistry of these radionuclides since 2000. The most comprehensive review of 188 Re radiopharmaceutical chemistry dates back to 1999 [11] and the reader is referred to that review for a summary of the state-of-the-art pre-2000, as well as to reviews published within the last decade covering bifunctional chelator and bioconjugation development for labelling peptides and proteins with both 99m Tc and 188 Re [12][13][14].…”

Diagnostic sensitivity of Tc-99m HYNIC PSMA SPECT/CT in prostate carcinoma: A comparative analysis with Ga-68 PSMA PET/CT

“…When Technetium‐99m HYNIC PSMA is used as the radiopharmaceutical, imaging is done with a gamma camera. There are more gamma cameras installed worldwide than there are PET cameras …”

“…There are more gamma cameras installed worldwide than there are PET cameras. 10 The synthesis and biodistribution of Tc-99m HYNIC PSMA in animals and humans have been reported. 11,12 Few studies have reported promising results with the use of Tc-99m-labeled PSMA ligand SPECT/CT imaging in patients with prostate carcinoma.…”